Literature DB >> 26130799

Discovering the first tyrosine kinase.

Tony Hunter1.   

Abstract

In the middle of the 20th century, animal tumor viruses were heralded as possible models for understanding human cancer. By the mid-1970s, the molecular basis by which tumor viruses transform cells into a malignant state was beginning to emerge as the first viral genomic sequences were reported and the proteins encoded by their transforming genes were identified and characterized. This was a time of great excitement and rapid progress. In 1978, prompted by the discovery from Ray Erikson's group that the Rous sarcoma virus (RSV) v-Src-transforming protein had an associated protein kinase activity specific for threonine, my group at the Salk Institute set out to determine whether the polyomavirus middle T-transforming protein had a similar kinase activity. Here, I describe the experiments that led to the identification of a kinase activity associated with middle T antigen and our serendipitous discovery that this activity was specific for tyrosine in vitro, and how this in turn led to the fortuitous observation that the v-Src-associated kinase activity was also specific for tyrosine. Our finding that v-Src increased the level of phosphotyrosine in cellular proteins in RSV-transformed cells confirmed that v-Src is a tyrosine kinase and transforms cells by phosphorylating proteins on tyrosine. My colleague Bart Sefton and I reported these findings in the March issue of PNAS in 1980. Remarkably, all of the experiments in this paper were accomplished in less than one month.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26130799      PMCID: PMC4491733          DOI: 10.1073/pnas.1508223112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Evidence that the phosphorylation of tyrosine is essential for cellular transformation by Rous sarcoma virus.

Authors:  B M Sefton; T Hunter; K Beemon; W Eckhart
Journal:  Cell       Date:  1980-07       Impact factor: 41.582

2.  Transforming gene product of Rous sarcoma virus phosphorylates tyrosine.

Authors:  T Hunter; B M Sefton
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

3.  An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates.

Authors:  W Eckhart; M A Hutchinson; T Hunter
Journal:  Cell       Date:  1979-12       Impact factor: 41.582

4.  Phosphorylation of polyoma T antigens.

Authors:  B S Schaffhausen; T L Benjamin
Journal:  Cell       Date:  1979-12       Impact factor: 41.582

5.  Product of in vitro translation of the Rous sarcoma virus src gene has protein kinase activity.

Authors:  B M Sefton; T Hunter; K Beemon
Journal:  J Virol       Date:  1979-04       Impact factor: 5.103

6.  Rapid enhancement of protein phosphorylation in A-431 cell membrane preparations by epidermal growth factor.

Authors:  G Carpenter; L King; S Cohen
Journal:  J Biol Chem       Date:  1979-06-10       Impact factor: 5.157

7.  Origin and functional properties of the major gene product of the Snyder-Theilen strain of feline sarcoma virus.

Authors:  M Barbacid; K Beemon; S G Devare
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

8.  Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine.

Authors:  O N Witte; A Dasgupta; D Baltimore
Journal:  Nature       Date:  1980-02-28       Impact factor: 49.962

9.  Avian sarcoma virus-transforming protein, pp60src shows protein kinase activity specific for tyrosine.

Authors:  M S Collett; A F Purchio; R L Erikson
Journal:  Nature       Date:  1980-05-15       Impact factor: 49.962

10.  Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.

Authors:  H Ushiro; S Cohen
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

View more
  9 in total

1.  Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers.

Authors:  Luke J Nelson; Heather J Wright; Nguyen B Dinh; Kevin D Nguyen; Olga V Razorenova; F Scott Heinemann
Journal:  Am J Pathol       Date:  2019-12-13       Impact factor: 4.307

2.  A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.

Authors:  Ernest Turro; Daniel Greene; Anouck Wijgaerts; Chantal Thys; Claire Lentaigne; Tadbir K Bariana; Sarah K Westbury; Anne M Kelly; Dominik Selleslag; Jonathan C Stephens; Sofia Papadia; Ilenia Simeoni; Christopher J Penkett; Sofie Ashford; Antony Attwood; Steve Austin; Tamam Bakchoul; Peter Collins; Sri V V Deevi; Rémi Favier; Myrto Kostadima; Michele P Lambert; Mary Mathias; Carolyn M Millar; Kathelijne Peerlinck; David J Perry; Sol Schulman; Deborah Whitehorn; Christine Wittevrongel; Marc De Maeyer; Augusto Rendon; Keith Gomez; Wendy N Erber; Andrew D Mumford; Paquita Nurden; Kathleen Stirrups; John R Bradley; F Lucy Raymond; Michael A Laffan; Chris Van Geet; Sylvia Richardson; Kathleen Freson; Willem H Ouwehand
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

3.  The Chromatin Assembly Factor Complex 1 (CAF1) and 5-Azacytidine (5-AzaC) Affect Cell Motility in Src-transformed Human Epithelial Cells.

Authors:  Akinori Endo; Tony Ly; Raffaella Pippa; Dalila Bensaddek; Armel Nicolas; Angus I Lamond
Journal:  J Biol Chem       Date:  2016-11-21       Impact factor: 5.157

Review 4.  Kirsten Ras* oncogene: significance of its discovery in human cancer research.

Authors:  Nobuo Tsuchida; Avaniyapuram Kannan Murugan; Michele Grieco
Journal:  Oncotarget       Date:  2016-07-19

Review 5.  The (Patho)Biology of SRC Kinase in Platelets and Megakaryocytes.

Authors:  Lore De Kock; Kathleen Freson
Journal:  Medicina (Kaunas)       Date:  2020-11-24       Impact factor: 2.430

Review 6.  Structural insights into redox-active cysteine residues of the Src family kinases.

Authors:  David E Heppner
Journal:  Redox Biol       Date:  2021-03-05       Impact factor: 11.799

Review 7.  Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents.

Authors:  David L Brautigan; Caroline Farrington; Goutham Narla
Journal:  Clin Sci (Lond)       Date:  2021-07-16       Impact factor: 6.876

Review 8.  Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

Authors:  Qinlian Jiao; Lei Bi; Yidan Ren; Shuliang Song; Qin Wang; Yun-Shan Wang
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

9.  Status of kinases in Epstein-Barr virus and Helicobacter pylori Coinfection in gastric Cancer cells.

Authors:  Charu Sonkar; Tarun Verma; Debi Chatterji; Ajay Kumar Jain; Hem Chandra Jha
Journal:  BMC Cancer       Date:  2020-09-29       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.